Novavax vaccine protects 96.4%

A new vaccine from the USA is now supposed to make its contribution to fighting the pandemic: With a 96.4 percent effectiveness, Novavax is another ray of hope in the crisis

According to the company, a vaccine candidate from the US manufacturer Novavax offers a high level of protection against the original corona virus and the highly contagious British variant.

Great Britain secures the first vaccine doses

The effectiveness against "mild, moderate and severe illnesses caused by the original Covid-19 strain" is 96.4 percent, said Novavax. This means: 96.4 percent fewer diseases occurred among the test subjects in the vaccinated group than among those in the control group.

British Health Secretary Matt Hancock spoke of "really encouraging results". Britain has ordered 60 million doses of the vaccine. Hancock stressed on Friday that these cans are made in northeast England.

New vaccine also protects against B.1.1.7

According to the results from the Phase III study in Great Britain, the protein-based vaccine NVX-CoV2373 has an effectiveness of 86.3 percent against variant B.1.1.7, which initially appeared in southern England, Novavax said. The entire data is based on 106 infections. Around 15,000 people between the ages of 18 and 84 took part in the study.

The European Medicines Agency (EMA) has already started a review process for the vaccine.

Coronavirus vaccination infection